Company Overview - Akari Therapeutics is a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for cancer treatment [3] - The company has developed its first novel payload, PH1, which is a spliceosome modulator designed to disrupt RNA splicing within cells [3] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers the PH1 payload directly into tumors [3] Product Development - PH1 is differentiated from current ADC payloads that typically use Topoisomerase1 inhibitors or tubulin inhibitors, showing potential to induce cancer cell death while activating immune cells [3] - In preclinical studies, AKTX-101 has demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - AKTX-101 has the potential to work synergistically with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination with these inhibitors [3] Upcoming Events - Akari Therapeutics will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:00 PM ET [1]

Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [3] - The company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3] Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for treating relapsed or refractory AML [4] - Following a successful Phase 1B/2 study (MB-106) and FDA input, the company believes it has de-risked the development pathway for Annamycin's potential approval for AML [4] Additional Drug Development - Moleculin is also developing WP1066, an Immune/Transcription Modulator targeting brain tumors and pancreatic cancers by inhibiting oncogenic transcription factors and stimulating immune response [5] - The company is working on a portfolio of antimetabolites, including WP1122, aimed at treating pathogenic viruses and certain cancer indications [5] Upcoming Events - Moleculin will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 20, 2025, at 2:00 PM ET, with CEO Walter Klemp as the presenter [1]

Core Viewpoint - Jet.AI Inc. has made a capital contribution to AIIA Sponsor Ltd., which is sponsoring AI Infrastructure Acquisition Corp., a special purpose acquisition company aiming for an initial public offering (IPO) focused on AI and machine learning technology companies [1][2]. Group 1: Company Overview - Jet.AI Inc. is a provider of high-performance GPU infrastructure and AI cloud services, transitioning to a pure-play AI data center company [5]. - The company was founded in 2018 and is based in Las Vegas, NV, operating in two segments: Software and Aviation [5]. - Jet.AI aims to build scalable, high-performance infrastructure to meet the growing computational demands of artificial intelligence [5]. Group 2: IPO Details - AI Infrastructure Acquisition Corp. plans to conduct an IPO with a base offering size of $100 million, potentially increasing to $115 million if the underwriters fully exercise their over-allotment option [2]. - The IPO will focus on high-impact private technology companies that advance AI and machine learning capabilities, as well as those involved in next-generation data center infrastructure [2]. - Maxim Group LLC is acting as the sole book-running manager for the IPO [3].

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Presentation - Senti Bio will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:20 PM ET [1] - The presentation will be led by Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio [1] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Wrap PAN-DA launches Kevlar tethers from existing BolaWrap 150 product line designed to physically entangle and disable hostile drones midair—deepens offerings into DoD and estimated $6.8B global counter-UAS marketMIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (NASDAQ: WRAP) (the “Company” or “Wrap”), a global leader in innovative public safety technology, today announced its second research and development counter-unmanned aircraft systems (C-UAS) initiative and released a Phase One video ...

Live video webcast on Wednesday, August 20th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as foll ...

LAS VEGAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- All American Gold Corp. (OTC: AAGC) is delighted to update the public about the Company’s exciting new concept in the Beauty industry. Hollywood Star Cuts (A Family Salon) and All American Gold Corp. (AAGC) have finalized an agreement with a Franchise group based in San Diego, CA, to launch a concept that will complement the proven Hollywood Star Cuts model in exclusive areas. Hollywood Star Salons is an exciting new platform set to debut in October 2025 in Encin ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has completed its previously announced bought deal private placement offering of securities, including the exercise in full of the Underwriter’s (as defined below) over-allotment option, of a total of 9,288,462 units of the Company (the “Offered ...

Core Viewpoint - VERSES AI Inc. has developed a robotics model that can perform household tasks without pre-training, achieving a success rate of 66.5%, surpassing the previous best of 54.7% [4][14]. Group 1: Robotics Model Capabilities - The VERSES robotics architecture can perform tasks such as tidying a room, preparing groceries, and setting a table more effectively than other models, without requiring pre-training [2][4]. - Current robotics systems are often inflexible and require extensive training data, making them costly and unreliable in dynamic environments [3][4]. - The VERSES model adapts to its environment quickly, overcoming challenges that typically hinder other robotics solutions [3][5]. Group 2: Comparison with Existing Technologies - The VERSES model achieved a success rate of 66.5% in three tasks compared to 54.7% for the leading deep learning alternative, which required 1.3 billion steps for pre-training [4][14][15]. - Existing robotics solutions often struggle with unexpected situations, leading to operational halts, while VERSES technology allows for adaptability without extensive prior training [11][12]. Group 3: Technological Innovation - VERSES technology equips robots with a world model, enabling them to execute tasks in various layouts without needing detailed instructions [12][13]. - The system consists of three modules that work together to adapt to unexpected objects and situations, enhancing operational reliability [13][17]. - The potential applications for VERSES technology span across industries, including factories, warehouses, and domestic environments, indicating a transformative impact on automation [5][15].

Core Insights - North Media reported Q2 2025 revenue of DKK 342 million, slightly down from DKK 343 million in Q2 2024, with a stable trend in Last Mile services and a 2% increase in Digital Services driven by BoligPortal [1] - The company has revised its full-year revenue guidance for 2025 to DKK 1,270–1,315 million, down from the previous range of DKK 1,280–1,337 million, while EBITDA and EBIT guidance has been upgraded [2][5] - The improvement in EBITDA and EBIT is primarily due to enhanced operations at SDR, leading to more stable planning and lower unit costs, with Bekey also contributing positively [3] Financial Performance - Q2 2025 EBITDA was DKK 48 million, down from DKK 61 million in Q2 2024, and EBIT was DKK 32 million compared to DKK 44 million in the previous year [1] - The revised guidance for 2025 includes EBITDA expectations of DKK 105–130 million, up from DKK 80–115 million, and EBIT expectations of DKK 50–75 million, up from DKK 25–60 million [2][5] Business Segments - North Media operates in two main business areas: Last Mile, which includes FK Distribution and SDR Svensk Direktreklam, and Digital Services, which encompasses BoligPortal, Dayli (MineTilbud), and Bekey [7] - The Last Mile segment is experiencing a slight loss in volumes, while growth in Digital Services, particularly BoligPortal and Dayli, has been lower than expected [4]